Disease relevance of Morganella

• Aztreonam was found to be more active than third-generation cephalosporins and comparable with mezlocillin against Enterobacter spp., Morganella, and Citrobacter freundii [1].
• Colonisation of the oropharyngeal cavity or intestine or both by strains resistant to polymyxin E occurred in 8% of patients (invariably Proteus and Morganella species) [2].
• The hdc gene coding for the pyridoxal 5'-phosphate dependent histidine decarboxylase from Morganella morganii has been expressed in Escherichia coli under control of the lac promoter [3].
• BMS-180680 had moderate activities (MIC90s of 2 to 8 microg/ml) against Citrobacter freundii, Morganella morganii, Shigella spp., and non-E. aerogenes Enterobacter spp [4].
• ESBL production did not raise the MICs of doripenem for Escherichia coli transconjugants, and studies with known expression mutants confirmed that neither inducible nor depressed AmpC beta-lactamase expression was protective in Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, or Morganella morganii [5].

High impact information on Morganella

• A pyridoxal 5'-phosphate-dependent histidine decarboxylase from Morganella morganii AM-15 was purified to homogeneity [6].
• Morganella AmpCs exhibit the highest catalytic efficiencies (k(cat)/K(m)) on classical penicillins, cefoxitin, narrow-spectrum cephalosporins, and cefotaxime [7].
• AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii [8].
• A new natural TEM-2 derivative, named TEM-72, was identified in a Proteus mirabilis strain and in a Morganella morganii strain isolated in Italy in 1999 [9].
• Molecular characterization of a ceftazidime-resistant Morganella morganii isolate producing a TEM-10 beta-lactamase [10].

Chemical compound and disease context of Morganella

• Only combinations with tazobactam and sulbactam were effective against the Morganella infection [11].
• A clinical isolate of Morganella morganii, with reduced susceptibility to expanded-spectrum cephalosporins and aztreonam, was found to produce an extended-spectrum beta-lactamase with a pI of 6 [12].
• In Morganella morganii, sparfloxacin and ciprofloxacin enhanced urease activity, particularly at the initial phase of growth [13].
• Clavulanic acid frequently enhanced the activity of ticarcillin against Xanthomonas maltophilia, and tazobactam frequently enhanced the activity of piperacillin against Morganella morganii [14].
• Combinations with tazobactam and sulbactam, but not clavulanic acid, were effective against Morganella spp [11].

Biological context of Morganella

• 7% DNA sequence identity with the ampC gene of Morganella morganii [15].
• Tigemonam was not hydrolyzed by the common plasmid beta-lactamases such as TEM-1 and SHV-1 or by the chromosomal beta-lactamases of Enterobacter, Morganella, Pseudomonas, and Bacteroides spp [16].
• OBJECTIVES: We analysed the architecture and probable origin of a class 1 integron from cefotaxime-resistant Morganella morganii isolates [17].
• Phosphorylation of nucleosides by the mutated acid phosphatase from Morganella morganii [18].
• In an in vitro assay with the plasma of these animals, an increased bactericidal activity was detected against Morganella morganii (1 d postpartum) in both groups, but again a higher activity occurred in the lactulose group [19].

Anatomical context of Morganella

• OBJECTIVE: This paper reports a case of chorioamnionitis due to Morganella morganii in a mother who presented with ruptured membranes at 24 weeks' gestation and was treated with dexamethasone and prophylactic ampicillin [20].

Gene context of Morganella

• The Morganella morganii phoC gene, encoding a class A acid phosphatase, was used to generate gene fusions with modified amino-terminal moieties of the Escherichia coli lacZ gene carrying a multiple-cloning site flanked by phage-specific promoters and recognition sites for universal sequencing primers [21].
• Synergistic inhibition was noted for beta-lactamase-containing, mecillinam-resistant Klebsiella, Citrobacter, Serratia, and Salmonella isolates, but only 18% of beta-lactamase-containing Proteus mirabilis, Providencia rettgeri, Providencia stuartii, and Morganella morganii were synergistically inhibited by the combinations [22].
• An increase in inoculum from 10(4) to 10(6) cfu raised faropenem MICs for Morganella morganii from 0.06-1 mg/L to 2-4 mg/L and for MRSA from 0.25-2 mg/L to 8 mg/L (a similar increase was not observed for MSSA) [23].
• The lipopolysaccharide of the bacterium Morganella morganii (strain KF 1676, RK 4222) yielded two polysaccharides, PS1 and PS2, when subjected to mild acid degradation followed by GPC [24].
• Salmonella enteritidis: AmpC plasmid-mediated inducible beta-lactamase (DHA-1) with an ampR gene from Morganella morganii [15].

Analytical, diagnostic and therapeutic context of Morganella

• With the exception of tests with Enterobacter spp. and Morganella morganii, the ceftriaxone minimum inhibitory concentration (MIC) result interpretive criteria predicted bacterial susceptibility (or resistance) to cefpodoxime with an acceptable rate of serious interpretive errors (1.5%) and an absolute categorical agreement > 92% [25].
• "Free" and "bound" Morganella morganii endotoxin was characterized by chemical (determination of proteins, saccharides and 3-deoxy-2-octulosonic acid) and immunochemical (double-diffusion test, immunoelectrophoresis, tandem crossed immunoelectrophoresis) methods [26].

References